This conclusion is based on studies where laboratory animals given semaglutide, liraglutide, tirzepatide and other GLP-1 medications developed tumors
Why Consider Microdosing GLP1 in Menopause & Perimenopause
Ozempic also carries the risk of more serious health concerns , including: Patients should be educated about the signs of serious side effects, like severe abdominal pain, persistent vomiting, or symptoms of low blood sugar
Use a fresh U-100 insulin syringe (29-31G, 0.3 mL or 0.5 mL) for every individual dose
Semaglutide weight loss by dose 0.25 mg : Starter dose, so minimal weight loss 0.5-1 mg: Moderate weight loss of about 5-7% at 3-6 months, and up to 7% at 28-68 weeks 1.7 mg: 10-12% weight loss at 28-68 weeks 2.4 mg: 15% average weight loss at 68-104 weeks What if the side effects are too strong